Abstract
Nasopharyngeal carcinoma (NPC) has distinct epidemiological and histological features among head and neck cancers.Clinical signs in patients with NPC change according to the tumor size and the status of lymph node metastases.Tumor can expand anteriorly to nasal cavity, pterygoid fossa or maxillary sinus, laterally to parapharyngeal spaceand infratemporal fossa, or posterosuperiorly to cranial base, clivus and intracranial structures. Radiotherapy is theprimary treatment in NPC. In tertiary centers, intensity modulated radiotherapy (IMRT) is the preferred radiotherapymodule. Concurrent chemoradiotherapy is the standard treatment of locally advanced NPC. Standard regimenincludes radiation to 70 Gy to the gross tumor in daily fractions of 2 Gy and additional chemotherapy which includes100 mg/m2 of cisplatin every 3 weeks or 30-40 mg/m2 once a week.In this article, updated staging in American Joint Committe on Cancer (AJCC) 8th edition guidelines, diagnosticmethods and treatment modalities in NPC are reviewed and presented in the light of current literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
